Licensing Ready TiPs TiPs pipeline is progressing through animal studies and human trials with FDA-aligned profiles that match oral drug specs while reducing GI side effects and swallowing difficulties, making it attractive for licensing partnerships.

End-to-End CDMO Greene Street combines formulation development with direct manufacturing, enabling end-to-end partnerships and faster onboarding for licensees; ideal for co-development and contract manufacturing deals.

Lean Agile A small team enables flexible collaboration terms, rapid decision cycles, and customized programs tailored to early-stage pharma partners seeking low-risk engagements.

US-Based Advantage Located in Doylestown, Pennsylvania, the company offers regulatory familiarity and onshore manufacturing proximity, appealing to US and North American pharma partners seeking reliable supply chains.

Transdermal Market Fit The transdermal focus targets patient groups with swallowing difficulties and GI tolerability needs, aligning with growing demand for alternative delivery routes and providing opportunities with portfolios in analgesia, chronic diseases, and related therapies.